News
AKTX
4.260
+6.68%
0.267
Weekly Report: what happened at AKTX last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at AKTX last week (0708-0712)?
Weekly Report · 07/15 09:54
Weekly Report: what happened at AKTX last week (0701-0705)?
Weekly Report · 07/08 09:55
Weekly Report: what happened at AKTX last week (0624-0628)?
Weekly Report · 07/01 09:55
Weekly Report: what happened at AKTX last week (0617-0621)?
Weekly Report · 06/24 09:58
Akari Therapeutics 13D Filing Shows Charles Steve Theofilos, M.D. Reported A Stake Of 9.99% In The Co As Of May 31, 2024
Benzinga · 06/18 20:20
CHARLES STEVE THEOFILOS FILES TO REPORT STAKE OF 9.99% IN AKARI THERAPEUTICS PLC AS OF MAY 31, 2024 - SEC FILING
Reuters · 06/18 20:17
Weekly Report: what happened at AKTX last week (0610-0614)?
Weekly Report · 06/17 09:55
12 Health Care Stocks Moving In Tuesday's Intraday Session
Elutia (NASDAQ:ELUT) stock rose 24.2% to $4.31 during Tuesday's regular session. Trinity Biotech stock rose 20.61% and Akari Therapeutics shares moved upwards by 20.26%. The company's Q1 earnings report came out today.
Benzinga · 06/11 16:31
Weekly Report: what happened at AKTX last week (0603-0607)?
Weekly Report · 06/10 09:56
SAMIR R. PATEL REPORTS 14.5% STAKE IN AKARI THERAPEUTICS PLC AS OF MAY 31 - SEC FILING
Reuters · 06/07 22:03
Akari Therapeutics announces interm CEO employment contract
Healthcare Akari Therapeutics announces interm CEO employment contract. Dr. Patel's employment contract includes no cash compensation, severance package or performance bonuses. Samir R. Patel will be compensated solely with equity, aligning his interests with Akari's shareholders.
Seeking Alpha · 06/05 12:53
Akari Therapeutics Announces Samir R. Patel, M.D., Has Assumed The Role Of Interim President & CEO, Increases Ownership To 14.2% With $1.25M Investment In Recent Private Placement
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement. Akari Therapeutics Plc is an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases.
Benzinga · 06/05 12:11
AKARI THERAPEUTICS PLC<AKTX.O> - SAMIR R. PATEL HAS ASSUMED ROLE OF INTERIM PRESIDENT & CEO
Reuters · 06/05 12:00
AKARI THERAPEUTICS ANNOUNCES INTERIM CEO EMPLOYMENT CONTRACT DEMONSTRATING ALIGNMENT WITH SHAREHOLDERS
Reuters · 06/05 12:00
Akari Therapeutics Secures $7.6M In Upsized Financing Round From Both New And Existing Investors
Benzinga · 06/04 12:24
Akari Therapeutics raises $7.6M in upsized financing round
Seeking Alpha · 06/04 12:17
AKARI THERAPEUTICS SECURES $7.6 MILLION IN UPSIZED FINANCING ROUND
Reuters · 06/04 12:00
Weekly Report: what happened at AKTX last week (0527-0531)?
Weekly Report · 06/03 09:57
BUZZ-U.S. STOCKS ON THE MOVE-Agilent, Best Buy, C3.ai
U.S. Stock index futures pared early losses on Thursday. Data showed the economy grew more slowly in the first quarter than previously estimated. Top three NYSE percentage gainers: Phoenix New Media, Best Buy, Burlington Stores. Dow e-minis down for the day.
Reuters · 05/30 13:13
More
Webull provides a variety of real-time AKTX stock news. You can receive the latest news about Akari Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About AKTX
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.